What is Humanscape?
Humanscape operates at the intersection of technology and patient advocacy, primarily through its flagship platform, RareNote. This digital ecosystem is designed to aggregate critical health data, thereby expanding treatment opportunities for patients suffering from rare and intractable diseases. By facilitating a more efficient connection between patients, researchers, and pharmaceutical developers, Humanscape addresses a significant unmet need in the global medical community.
Beyond its focus on rare diseases, the company maintains a diversified portfolio with Mamitalk, a specialized platform dedicated to pregnancy and parenting. This dual-pronged approach allows Humanscape to capture significant user engagement across different life stages, reinforcing its position as a versatile health tech innovator. The company's commitment to providing innovative solutions for families dealing with complex health challenges has established it as a critical infrastructure provider in the digital health space.
How much funding has Humanscape raised?
Humanscape has raised a total of $3.8M across 1 funding round:
Other Financing Round
$3.8M
Other Financing Round (2025): $3.8M with participation from Naver, Korea Investment Partners, and Daewoong Investment
Key Investors in Humanscape
Naver
Naver Corporation is a South Korean internet conglomerate and search engine pioneer that invests in AI, robotics, and digital services to foster interconnected technological ecosystems.
Korea Investment Partners
A leading South Korean financial holding company specializing in investment banking, asset management, and private equity to support long-term corporate growth.
Daewoong Investment
A venture capital and private equity firm focused on identifying and scaling high-potential enterprises within the healthcare and technology sectors.
What's next for Humanscape?
Looking ahead, Humanscape is poised to leverage its recent strategic investment to scale its data analytics capabilities and expand its footprint in the global healthcare market. The focus will likely shift toward enhancing the interoperability of its platforms, ensuring that patient-generated data can be seamlessly integrated into clinical research workflows. As the company matures, it will likely prioritize partnerships with global pharmaceutical firms to further validate its RareNote platform as a standard tool for rare disease clinical trials.
Furthermore, the company is expected to invest heavily in artificial intelligence and machine learning to derive deeper insights from its existing user base. By optimizing its operational efficiency and expanding its reach, Humanscape aims to solidify its role as a leader in the digital health transformation, ultimately improving patient outcomes on a global scale.
